首页> 外文期刊>Expert opinion on therapeutic targets >Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials.
【24h】

Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials.

机译:内皮素受体调节剂的治疗潜力:来自人类临床试验的经验教训。

获取原文
获取原文并翻译 | 示例
           

摘要

The endothelin system, and in particular endothelin receptors, are targets for therapeutic intervention in human diseases. Endothelin receptor antagonists have reached clinical use for treating pulmonary arterial hypertension, and are under clinical investigation for several other diseases, such as cancer, vasospasm or fibrogenic diseases. We review the molecules that have been evaluated in the main clinical trials, from the point of view of receptor selectivity and of their chemical characteristics which were important for efficacy in pulmonary hypertension. We will also discuss future use of antagonists to endothelin receptor(s) in several human diseases and what should be the necessary properties of the future molecules for efficacy in diseases where the presently tested molecules displayed suboptimal efficacy.
机译:内皮素系统,特别是内皮素受体,是人类疾病治疗干预的靶标。内皮素受体拮抗剂已经在临床上用于治疗肺动脉高压,并且正在临床研究其他几种疾病,例如癌症,血管痉挛或纤维化疾病。从受体选择性及其化学特性的观点出发,我们综述了在主要临床试验中评估过的分子,这些分子对于肺动脉高压的疗效至关重要。我们还将讨论内皮素受体拮抗剂在几种人类疾病中的未来用途,以及在目前测试的分子显示出次佳疗效的疾病中,未来分子在疾病中的疗效应具有哪些必要特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号